Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable and Borderline Resectable Pancreatic Cancer
Hidenori Takahashi(Osaka International Cancer Institute), Osamu Ishikawa(Gunma University), Masahiko Yano(Nagoya Sangyo University), Masayuki Murata(Toyo University), Tatsuya Ioka(National Cancer Center Hospital East), Hiroaki Ohigashi(Teine Keijinkai Hospital), Terumasa Yamada, Shigeru Marubashi(Osaka International Cancer Institute), Kunihito Gotoh(Osaka International Cancer Institute), Hiroyuki Uehara(Osaka International Cancer Institute)
Cited by 171
Related Papers
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
|Journal of Clinical Oncology|2013|632
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
|The Lancet Oncology|2011|396
Practical Usefulness of Lymphatic and Connective Tissue Clearance for the Carcinoma of the Pancreas Head
|Annals of Surgery|1988|373
Genome-wide Expression Analysis of Mouse Liver Reveals CLOCK-regulated Circadian Output Genes
|Journal of Biological Chemistry|2003|347